NEWS Release

Peru Grants Authorization

Date: March 29, 2004

Toronto Stock Exchange Trading Symbol: WXI
http://www.wextech.ca
E-mail: wex@wextech.ca

International Wex Technologies Inc . (the "Company") is pleased to announce that through its subsidiary, Acro Pharm Corp. (formerly GlobalMed Corp.), and its distributor in Peru, a Sanitary Registry Authorization has been obtained for our product TetrodoninT (a product derived from our platform drug)

This allows the Company to sell our product in Peru . Prior to sales, our distribution agreement states that clinical trials will be undertaken in that country. A clinical trial in Peru is now in the planning. The trial will be a double-blind, randomized, placebo-controlled, fixed repeated-dose efficacy and safety study to determine the efficacy of TetrodoninT in decreasing drug use and the severity of drug withdrawal symptoms and to assess its safety and tolerability for therapeutic use in drug-dependent subjects.

Acro Pharm Corp. will coordinate the project with the Peruvian distributor to conduct the clinical trial. The timeline for commencement of this trial has not yet been established. Further details will be announced as the project progresses.

International Wex Technologies Inc., a publicly listed neuro-bioscience company (WXI), is focused on the development and commercialization of innovative drug products, primarily for pain management. The Company's lead compound, Tetrodotoxin, is a sodium channel blocker and is the platform for the Company's development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

For additional information on our products visit us at http://www.wextech.ca or call Gordon Stanley, Corporate Communications at 604-683-8880, or at 1-800-722-7549.

Per: Donna Shum, Corporate Secretary

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this News Release.